This randomized, multicenter, double-blind clinical trial assessed the safety and efficacy of intravenous ferumoxytol compared to ferric carboxymaltose (FCM) in patients with iron deficiency anemia (IDA) unresponsive or intolerant to oral iron. A total of 1,997 patients received either ferumoxytol (n=997) or FCM (n=1000) over ≥15 minutes on days 1
